Cellosaurus logo
expasy logo

Cellosaurus KTC1res.2 (CVCL_A2CT)

[Text version]
Cell line name KTC1res.2
Synonyms KTC1res_2; Res.2 KTC1
Accession CVCL_A2CT
Resource Identification Initiative To cite this cell line use: KTC1res.2 (RRID:CVCL_A2CT)
Comments Population: Japanese.
Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
Sequence variations
  • Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=29156680).
  • Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=29156680).
  • Mutation; HGNC; 9801; RAC1; Simple; p.Asp63Val (c.188A>T); Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Heterozygous; Note=In promoter (from parent cell line).
Disease Poorly differentiated thyroid gland carcinoma (NCIt: C6040)
Thyroid carcinoma (ORDO: Orphanet_100088)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_6300 (KTC-1)
Sex of cell Male
Age at sampling 68Y
Category Cancer cell line
Publications

PubMed=29156680; DOI=10.18632/oncotarget.21262; PMCID=PMC5689570
Antonello Z.A., Hsu N., Bhasin M., Roti G., Joshi M., Van Hummelen P., Ye E., Lo A.S., Karumanchi S.A., Bryke C.R., Nucera C.
Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF(V600E).
Oncotarget 8:84743-84760(2017)

Cross-references
Cell line databases/resources cancercelllines; CVCL_A2CT
Encyclopedic resources Wikidata; Q105509842
Polymorphism and mutation databases Cosmic; 2755724
Entry history
Entry creation12-Jan-2021
Last entry update05-Oct-2023
Version number6